These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 11151970)

  • 1. Micronized purified flavonoid fraction and the treatment of chronic venous insufficiency: microcirculatory mechanisms.
    Smith PD
    Microcirculation; 2000; 7(6 Pt 2):S35-40. PubMed ID: 11151970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing.
    Coleridge Smith PD
    Angiology; 2003; 54 Suppl 1():S45-50. PubMed ID: 12934756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microcirculatory dysfunction in chronic venous insufficiency (CVI).
    Jünger M; Steins A; Hahn M; Häfner HM
    Microcirculation; 2000; 7(6 Pt 2):S3-12. PubMed ID: 11151969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deleterious effects of white cells in the course of skin damage in CVI.
    Coleridge Smith PD
    Int Angiol; 2002 Jun; 21(2 Suppl 1):26-32. PubMed ID: 12515977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF).
    Bush R; Comerota A; Meissner M; Raffetto JD; Hahn SR; Freeman K
    Phlebology; 2017 Apr; 32(1_suppl):3-19. PubMed ID: 28211296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of adhesion molecules: a new target for the treatment of chronic venous insufficiency.
    Verbeuren TJ; Bouskela E; Cohen RA; Vanhoutte PM
    Microcirculation; 2000; 7(6 Pt 2):S41-8. PubMed ID: 11151971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Chronic venous insufficiency].
    Veraart JC
    Ned Tijdschr Geneeskd; 2002 Feb; 146(5):199-203. PubMed ID: 11851078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of micronized purified flavonoid fraction: an overview.
    Struckmann JR
    J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic management of chronic venous insufficiency: microcirculation as a target.
    Bergan JJ; Schmid-Schönbein GW
    Microcirculation; 2000; 7(6 Pt 2):S23-8. PubMed ID: 11151967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic aspects of a phlebotropic drug in CVI-associated edema.
    Ramelet AA
    Angiology; 2000 Jan; 51(1):19-23. PubMed ID: 10667639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy.
    Murphy MA; Joyce WP; Condron C; Bouchier-Hayes D
    Eur J Vasc Endovasc Surg; 2002 Apr; 23(4):349-52. PubMed ID: 11991698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The causes of skin damage and leg ulceration in chronic venous disease.
    Smith PC
    Int J Low Extrem Wounds; 2006 Sep; 5(3):160-8. PubMed ID: 16928672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From symptoms to leg edema: efficacy of Daflon 500 mg.
    Nicolaides AN
    Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micronized purified flavonoid fraction (MPFF): a review of its pharmacological effects, therapeutic efficacy and benefits in the management of chronic venous insufficiency.
    Katsenis K
    Curr Vasc Pharmacol; 2005 Jan; 3(1):1-9. PubMed ID: 15641940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence.
    Nicolaides AN; Allegra C; Bergan J; Bradbury A; Cairols M; Carpentier P; Comerota A; Delis C; Eklof B; Fassiadis N; Georgiou N; Geroulakos G; Hoffmann U; Jantet G; Jawien A; Kakkos S; Kalodiki E; Labropoulos N; Neglen P; Pappas P; Partsch H; Perrin M; Rabe E; Ramelet AA; Vayssaira M; Ioannidou E; Taft A
    Int Angiol; 2008 Feb; 27(1):1-59. PubMed ID: 18277340
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study.
    Shoab SS; Scurr JH; Coleridge-Smith PD
    Eur J Vasc Endovasc Surg; 1999 Oct; 18(4):334-8. PubMed ID: 10550269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin perfusion pressure in leg ulcers assessed by photoplethysmography.
    Guillot B; Dandurand M; Guilhou JJ
    Int Angiol; 1988; 7(2 Suppl):33-4. PubMed ID: 3183454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical efficacy of micronized purified flavonoid fraction (MPFF) in edema.
    Olszewski W
    Angiology; 2000 Jan; 51(1):25-9. PubMed ID: 10667640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micronized Purified Flavonoid Fraction (MPFF) for Patients Suffering from Chronic Venous Disease: A Review of New Evidence.
    Ulloa JH
    Adv Ther; 2019 Mar; 36(Suppl 1):20-25. PubMed ID: 30758743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids.
    Lyseng-Williamson KA; Perry CM
    Drugs; 2003; 63(1):71-100. PubMed ID: 12487623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.